<DOC>
	<DOCNO>NCT00071760</DOCNO>
	<brief_summary>This 48-week study evaluate safety , tolerability , pharmacokinetics , antiviral activity investigational regimen include FDA approve HIV drug HIV-infected pediatric subject , age 4 week &lt; 2 year old .</brief_summary>
	<brief_title>Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects</brief_title>
	<detailed_description>A 48 week , Phase II , open-label , 2-cohort , multicenter study evaluate pharmacokinetics , safety , tolerability antiviral activity GW433908 GW433908/RTV administer HIV-1 infected protease inhibitor ( PI ) naive PI-experienced pediatric subject age 4 week &lt; 2 year .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Male female 4 week &lt; 2 year age . Cohort 1 ( 6 month &lt; 2 year ) : Subjects must &lt; 2 year age Week 2 visit therefore maximum age screen 22 month . Cohort 2 ( 4 week &lt; 6 month ) : Subjects must &lt; 6 month age Week 2 visit , therefore maximum age screen 4 month entry cohort . Parent legal guardian willing able provide write informed consent subject participate trial . Screening plasma HIV1 RNA level &gt; =400copies/mL . Subjects , investigator 's opinion , follow viral resistance test conduct , able construct active Nucleoside Reverse Transcriptase Inhibitor ( NRTI ) backbone regimen consist 2 NRTIs . Subjects must meet one follow criterion : Therapynaïve PInaïve subject ( define receive less one week PI ) . PIexperienced subject define prior experience three PIs . Prior RTVboosted PI therapy consider one PI long RTV dose low recommend use RTV antiretroviral agent . Prior history receive APV . NonNucleoside Reverse Transcriptase Inhibitor ( NNRTI ) therapy within 14 day prior study drug administration ( single multiple dose ) anticipate need concurrent NNRTI therapy study period . PI therapy within 5 day prior study drug administration ( applicable subject undergo single dose visit ) Subjects and/or parents/legal guardian , investigator 's opinion , able comply requirement study . Subject initial acute phase Centers Disease Control Prevention ( CDC ) Clinical Category C event infection ( per 1994 classification ) Baseline . Subject may enrol provide receive treatment infection , treatment contraindicate FPV , subject clinically improve Baseline visit . Presence malabsorption syndrome gastrointestinal dysfunction might interfere drug absorption render subject unable take oral medication . Presence serious medical condition ( e.g. , hemoglobinopathy , chronic anemia , diabetes , cardiac dysfunction , hepatitis , clinically relevant pancreatitis ) , opinion investigator , might compromise safety subject . Any acute laboratory abnormality screen , opinion investigator , preclude subject 's participation study investigational compound . If subject find acute Grade 4 laboratory abnormality screening , test may repeat within screen window . Any verified Grade 4 laboratory abnormality would exclude subject study participation . Grade 3 high ( &gt; 10x ULN ) serum aminotransferase level ( alanine aminotransferase , ALT and/or aspartate aminotransferase , AST ) within 28 day prior study drug administration / clinically relevant hepatitis within previous 6 month . Treatment radiation therapy cytotoxic chemotherapeutic agent within 28 day study drug administration anticipate need treatment within study period . Treatment immunomodulating agent ( e.g. , systemic corticosteroid , interleukin , interferon ) agent know antiHIV activity ( e.g. , hydroxyurea foscarnet ) within 28 day study drug administration . Treatment follow medication within 28 day prior receive study medication anticipate need study : Amiodarone , astemizole , bepridil , bupropion , cisapride , clorazepate , clozapine , diazepam , dihydroergotamine , encainide , ergonovine , ergotamine , estazolam , flecainide , flurazepam , lovastatin , meperidine , methylergonovine , midazolam , pimozide , piroxicam , propafenone , propoxyphene , quinidine , simvastatin , terfenadine , triazolam ( drug exclude safety reason ) . Carbamazepine , dexamethasone , phenobarbital , primidone , rifampin , St Johns Wort , ( drug exclude potential decrease plasma protease inhibitor concentration ) . Treatment investigational drugs/therapies within 28 day prior receive study medication ( note : treatment available Treatment IND expandedaccess mechanism evaluate casebycase basis consultation sponsor ) . History drug allergy , opinion investigator , contraindicate participation trial know hypersensitivity study medication ( e.g . document hypersensitivity nucleoside analogue ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>pediatrics</keyword>
	<keyword>ritonavir</keyword>
	<keyword>amprenavir</keyword>
	<keyword>AGENERASE</keyword>
	<keyword>HIV</keyword>
	<keyword>Lexiva</keyword>
	<keyword>protease inhibitor</keyword>
	<keyword>HIV Infection</keyword>
	<keyword>fosamprenavir</keyword>
</DOC>